אבטספט - Abatacept

אבטספט - Abatacept
התוויות	Orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease modifying anti rheumatic drugs (DMARDs) including methotrexate (MTX) or a TNF-alpha inhibitor. A reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate. Polyarticular juvenile idiopathic arthritis: Orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (JIA) in paediatric patients 6 years of age and older who have had an insufficient response to other DMARDs including at least one TNF inhibitor. Orencia has not been studied in children under 6 years old.

דרך מתן

אבטספט - Abatacept
שמות מסחריים	®ORENCIA


קבוצה פרמקולוגית (ATC)	"SELECTIVE IMMUNOSUPPRESSIVE AGENTS"
שם גנרי	"אבטספט" (קישור לדף התרופה במאגר משרד הבריאות)
סל הבריאות	לא כלול
התוויות	Orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease modifying anti rheumatic drugs (DMARDs) including methotrexate (MTX) or a TNF-alpha inhibitor. A reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate. Polyarticular juvenile idiopathic arthritis: Orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (JIA) in paediatric patients 6 years of age and older who have had an insufficient response to other DMARDs including at least one TNF inhibitor. Orencia has not been studied in children under 6 years old.
שם יצרן	BRISTOL MYERS SQUIBB SPA, ITALY
שם בעל הרישום	BRISTOL-MYERS SQUIBB (ISRAEL) LIMITED